Vaxcyte, Inc. PCVX Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by Vaxcyte, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableCurrent.
The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Vaxcyte, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Vaxcyte, Inc.'s accounts payable?
- Vaxcyte, Inc. (PCVX) reported accounts payable of $63.06M in Q1 2026.
- How has Vaxcyte, Inc.'s accounts payable changed year-over-year?
- Vaxcyte, Inc.'s accounts payable increased by 207.4% year-over-year, from $20.51M to $63.06M.
- What is the long-term trend for Vaxcyte, Inc.'s accounts payable?
- Over 4 years (2021 to 2025), Vaxcyte, Inc.'s accounts payable has grown at a 18.2% compound annual growth rate (CAGR), from $88.03M to $171.79M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.